Tolerance to nitroglycerin-induced preconditioning of the endothelium: a human in vivo study. 2010

Tommaso Gori, and Saverio Dragoni, and Giuseppe Di Stolfo, and Silvia Sicuro, and Andrew Liuni, and Mary Clare Luca, and George Thomas, and Matthias Oelze, and Andreas Daiber, and John D Parker
Department of Internal, Cardiovascular and Geriatric Medicine, University of Siena, Italy. Tommaso.gori@utoronto.ca

Damage and dysfunction of the vascular endothelium critically influence clinical outcomes after ischemia and reperfusion (I/R). Brief exposure to organic nitrates can protect the vascular endothelium from I/R injury via a mechanism that is similar to ischemic preconditioning and is independent of hemodynamic changes. The clinical relevance of these protective effects clearly depends on whether they can be sustained over time. Twenty-four healthy (age 25-32) male volunteers were randomized to receive 1) transdermal nitroglycerin (GTN; 0.6 mg/h) administered for 2 h on 1 day only, 2) transdermal GTN for 2 h/day for 7 days, or 3) continuous therapy with transdermal GTN for 7 days. Eight volunteers underwent continuous GTN therapy followed by intra-arterial infusion of the antioxidant vitamin C. Finally, five additional subjects underwent no therapy and served as controls. Endothelial function measurements were performed before and after induction of I/R of the arm. I/R caused a significant blunting of the flow responses to acetylcholine in the control group (P < 0.01 vs. before I/R). A single 2-h GTN dosage, given 24 h before I/R, prevented I/R-induced endothelial dysfunction [P = not significant (NS) vs. before I/R], but this protective effect was completely lost after 1 wk of GTN administration 2 h/day (P < 0.05 vs. before I/R; P = NS vs. control). In subjects who received continuous GTN, endothelial responses were blunted before I/R, and I/R did not cause further endothelial dysfunction. Finally, vitamin C normalized acetylcholine responses and prevented the loss of preconditioning associated with prolonged GTN. In a separate experimental model using isolated human endothelial cells, short-term incubation with GTN caused upregulation of heme oxygenase, an effect that was lost after prolonged GTN administration. Although a single administration of GTN is able to protect the endothelium from I/R-induced endothelial dysfunction, this protection is lost upon prolonged exposure, likely via an oxidative mechanism.

UI MeSH Term Description Entries
D007261 Infusions, Intra-Arterial Regional infusion of drugs via an arterial catheter. Often a pump is used to impel the drug through the catheter. Used in therapy of cancer, upper gastrointestinal hemorrhage, infection, and peripheral vascular disease. Infusions, Regional Arterial,Infusions, Intra Arterial,Infusions, Intraarterial,Arterial Infusion, Intra,Arterial Infusion, Regional,Arterial Infusions, Intra,Arterial Infusions, Regional,Infusion, Intra Arterial,Infusion, Intra-Arterial,Infusion, Intraarterial,Infusion, Regional Arterial,Intra Arterial Infusion,Intra Arterial Infusions,Intra-Arterial Infusion,Intra-Arterial Infusions,Intraarterial Infusion,Intraarterial Infusions,Regional Arterial Infusion,Regional Arterial Infusions
D008297 Male Males
D010991 Plethysmography Recording of change in the size of a part as modified by the circulation in it. Plethysmographies
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D004730 Endothelium, Vascular Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components. Capillary Endothelium,Vascular Endothelium,Capillary Endotheliums,Endothelium, Capillary,Endotheliums, Capillary,Endotheliums, Vascular,Vascular Endotheliums
D005996 Nitroglycerin A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives. Glyceryl Trinitrate,Anginine,Dynamite,Gilustenon,Nitrangin,Nitro-Bid,Nitro-Dur,Nitrocard,Nitroderm,Nitroderm TTS,Nitroglyn,Nitrol,Nitrolan,Nitrong,Nitrospan,Nitrostat,Perlinganit,Susadrin,Sustac,Sustak,Sustonit,Transderm Nitro,Tridil,Trinitrin,Trinitrolong,Nitro Bid,Nitro Dur,NitroBid,NitroDur,Trinitrate, Glyceryl
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000109 Acetylcholine A neurotransmitter found at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in the central nervous system. 2-(Acetyloxy)-N,N,N-trimethylethanaminium,Acetilcolina Cusi,Acetylcholine Bromide,Acetylcholine Chloride,Acetylcholine Fluoride,Acetylcholine Hydroxide,Acetylcholine Iodide,Acetylcholine L-Tartrate,Acetylcholine Perchlorate,Acetylcholine Picrate,Acetylcholine Picrate (1:1),Acetylcholine Sulfate (1:1),Bromoacetylcholine,Chloroacetylcholine,Miochol,Acetylcholine L Tartrate,Bromide, Acetylcholine,Cusi, Acetilcolina,Fluoride, Acetylcholine,Hydroxide, Acetylcholine,Iodide, Acetylcholine,L-Tartrate, Acetylcholine,Perchlorate, Acetylcholine
D000279 Administration, Cutaneous The application of suitable drug dosage forms to the skin for either local or systemic effects. Cutaneous Drug Administration,Dermal Drug Administration,Drug Administration, Dermal,Percutaneous Administration,Skin Drug Administration,Transcutaneous Administration,Transdermal Administration,Administration, Dermal,Administration, Transcutaneous,Administration, Transdermal,Cutaneous Administration,Cutaneous Administration, Drug,Dermal Administration,Drug Administration, Cutaneous,Skin Administration, Drug,Administration, Cutaneous Drug,Administration, Dermal Drug,Administration, Percutaneous,Administrations, Cutaneous,Administrations, Cutaneous Drug,Administrations, Dermal,Administrations, Dermal Drug,Administrations, Percutaneous,Administrations, Transcutaneous,Administrations, Transdermal,Cutaneous Administrations,Cutaneous Administrations, Drug,Cutaneous Drug Administrations,Dermal Administrations,Dermal Drug Administrations,Drug Administrations, Cutaneous,Drug Administrations, Dermal,Drug Skin Administrations,Percutaneous Administrations,Skin Administrations, Drug,Skin Drug Administrations,Transcutaneous Administrations,Transdermal Administrations

Related Publications

Tommaso Gori, and Saverio Dragoni, and Giuseppe Di Stolfo, and Silvia Sicuro, and Andrew Liuni, and Mary Clare Luca, and George Thomas, and Matthias Oelze, and Andreas Daiber, and John D Parker
February 2010, American journal of physiology. Heart and circulatory physiology,
Tommaso Gori, and Saverio Dragoni, and Giuseppe Di Stolfo, and Silvia Sicuro, and Andrew Liuni, and Mary Clare Luca, and George Thomas, and Matthias Oelze, and Andreas Daiber, and John D Parker
January 2013, Anesthesiology,
Tommaso Gori, and Saverio Dragoni, and Giuseppe Di Stolfo, and Silvia Sicuro, and Andrew Liuni, and Mary Clare Luca, and George Thomas, and Matthias Oelze, and Andreas Daiber, and John D Parker
August 1994, British journal of pharmacology,
Tommaso Gori, and Saverio Dragoni, and Giuseppe Di Stolfo, and Silvia Sicuro, and Andrew Liuni, and Mary Clare Luca, and George Thomas, and Matthias Oelze, and Andreas Daiber, and John D Parker
November 2004, Journal of cardiovascular pharmacology,
Tommaso Gori, and Saverio Dragoni, and Giuseppe Di Stolfo, and Silvia Sicuro, and Andrew Liuni, and Mary Clare Luca, and George Thomas, and Matthias Oelze, and Andreas Daiber, and John D Parker
September 2001, Circulation,
Tommaso Gori, and Saverio Dragoni, and Giuseppe Di Stolfo, and Silvia Sicuro, and Andrew Liuni, and Mary Clare Luca, and George Thomas, and Matthias Oelze, and Andreas Daiber, and John D Parker
December 2001, Biological & pharmaceutical bulletin,
Tommaso Gori, and Saverio Dragoni, and Giuseppe Di Stolfo, and Silvia Sicuro, and Andrew Liuni, and Mary Clare Luca, and George Thomas, and Matthias Oelze, and Andreas Daiber, and John D Parker
December 1987, Archives internationales de pharmacodynamie et de therapie,
Tommaso Gori, and Saverio Dragoni, and Giuseppe Di Stolfo, and Silvia Sicuro, and Andrew Liuni, and Mary Clare Luca, and George Thomas, and Matthias Oelze, and Andreas Daiber, and John D Parker
September 1987, The New England journal of medicine,
Tommaso Gori, and Saverio Dragoni, and Giuseppe Di Stolfo, and Silvia Sicuro, and Andrew Liuni, and Mary Clare Luca, and George Thomas, and Matthias Oelze, and Andreas Daiber, and John D Parker
May 2005, Circulation,
Tommaso Gori, and Saverio Dragoni, and Giuseppe Di Stolfo, and Silvia Sicuro, and Andrew Liuni, and Mary Clare Luca, and George Thomas, and Matthias Oelze, and Andreas Daiber, and John D Parker
November 2010, The Canadian journal of cardiology,
Copied contents to your clipboard!